Evidence map›Paper›PMID 28322973›Full record

ReviewPharmacology & therapeutics2017

Imidazoline I

Jun-Xu Li

Abstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2Journal of medicinal chemistry · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. PET imaging of reactive astrocytes in neurological disorders.European journal of nuclear medicine and molecular imaging · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Jun-Xu LiSchool of Pharmacy, Nantong University, Nantong, Jiangsu Province, China; Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA. Electronic address: junxuli@buffalo.edu.
Nantong University · CN

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
IMIDAZOLINE I2 RECEPTORS AS TARGETS FOR THE TREATMENT OF PAINR01DA034806 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, JUN-XU · 2013 to 2017
$1.7M
Behavioral effects of methamphetamine & imidazoline I2 receptor ligandsR21DA033426 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, JUN-XU · 2013 to 2014
$464k
NCATS NIH HHS UL1 TR001412NIDA NIH HHS R01 DA034806NIDA NIH HHS R21 DA033426
6 · The paper itself

Abstract

Since first introduced more than two decades ago, the research in imidazoline I

Indexed as

AnimalsHumansImidazoline ReceptorsLigandsImidazoline ReceptorsLigandsBody temperatureDrug discriminationImidazoline I(2) receptorNeuroprotectionPain

Identifiers

PMID28322973
PMCPMC5600648
OpenAlexW2595647051

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.